

Jazz Pharmaceuticals plc  
 Form 4  
 July 08, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**ENRIGHT PATRICK G**

(Last) (First) (Middle)

C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220

(Street)

MENLO PARK, CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**Jazz Pharmaceuticals plc [JAZZ]**

3. Date of Earliest Transaction (Month/Day/Year)  
**07/06/2015**

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |   |  |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|---|--|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |  |   |  |
|                                 |                                      |  |                                | Code  | V   | Amount   |  |   |  |
| Ordinary Shares                 | 07/06/2015                           |  | S                              | 1,078   | D   | \$ 175.8073 <sup>(1)</sup>                               | 293,029                                    | I | By Longitude Venture Partners, L.P. <sup>(2)</sup> |
| Ordinary Shares                 | 07/06/2015                           |  | S                              | 5,196   | D   | \$ 176.8559 <sup>(3)</sup>                               | 287,833                                    | I | By Longitude Venture Partners, L.P. <sup>(2)</sup> |
|                                 | 07/06/2015                           |  | S                              | 2,986   | D   |  | 284,847                                    | I |  |

Edgar Filing: Jazz Pharmaceuticals plc - Form 4

|                 |            |   |     |   |                       |         |   |  |   |
|-----------------|------------|---|-----|---|-----------------------|---------|---|--|---|
| Ordinary Shares |            |   |     |   | \$<br>177.7383<br>(4) |         |   |  | By<br>Longitude<br>Venture<br>Partners,<br>L.P. (2)   |
| Ordinary Shares | 07/06/2015 | S | 543 | D | \$<br>178.5941<br>(5) | 284,304 | I |  | By<br>Longitude<br>Venture<br>Partners,<br>L.P. (2)   |
| Ordinary Shares | 07/06/2015 | S | 22  | D | \$<br>175.8073<br>(6) | 5,871   | I |  | By<br>Longitude<br>Capital<br>Associates,<br>L.P. (2) |
| Ordinary Shares | 07/06/2015 | S | 105 | D | \$<br>176.8576<br>(7) | 5,766   | I |  | By<br>Longitude<br>Capital<br>Associates,<br>L.P. (2) |
| Ordinary Shares | 07/06/2015 | S | 60  | D | \$ 177.742<br>(8)     | 5,706   | I |  | By<br>Longitude<br>Capital<br>Associates,<br>L.P. (2) |
| Ordinary Shares | 07/06/2015 | S | 10  | D | \$ 178.591<br>(9)     | 5,696   | I |  | By<br>Longitude<br>Capital<br>Associates,<br>L.P. (2) |
| Ordinary Shares |            |   |     |   |                       | 1,650   | D |  |   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene Own Follo |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|----------------------------------|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|----------------------------------|

(A) or  
Disposed  
of (D)  
(Instr. 3,  
4, and 5)

Repor  
Trans  
(Instr

| Code | V | (A) | (D) | Date<br>Exercisable | Expiration<br>Date | Title | Amount<br>or<br>Number<br>of<br>Shares |
|------|---|-----|-----|---------------------|--------------------|-------|--|
|------|---|-----|-----|---------------------|--------------------|-------|--|

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director    10% Owner    Officer    Other

ENRIGHT PATRICK G  
C/O LONGITUDE CAPITAL PARTNERS, LLC  
800 EL CAMINO REAL, SUITE 220  
MENLO PARK, CA 94025

X

## Signatures

/s/ Patrick G.  
Enright

07/08/2015

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$175.27 to \$176.26. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(2) The Reporting Person is a managing member of Longitude Capital Partners, LLC, the general partner of each of Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. The Reporting Person disclaims beneficial ownership of the securities of the Issuer held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. except to the extent of his pecuniary interest therein.

(3) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$176.39 to \$177.37. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(4) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$177.39 to \$178.15. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(5) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$178.49 to \$178.92. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(6) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$175.27 to \$176.26. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the

## Edgar Filing: Jazz Pharmaceuticals plc - Form 4

sales were effected.

- (7) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$176.39 to \$177.37. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- (8) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$177.39 to \$178.15. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- (9) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$178.49 to \$178.76. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

### **Remarks:**

All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.